(MENAFN- ProactiveInvestors - N.America) Orphan disease specialist Baxalta (NYSE:BXLT) has dosed the first patient in its Phase 1 trial for BAX 826 a new treatment for haemophilia.
"This is an important step in evolving extended half-life treatments as we aim to improve bleed protection for heamophilia A patients while potentially offering once-weekly dosing' said John Orloff the US firm's chief scientific officer.
Extending the half-life means fewer injections of a clotting agent for haemophilia sufferers.
The compound has been modified from proprietary polysialic acid (PSA) technology licensed fromjunior Xenetic Biosciences(OTCQB: XBIO).
The partnership was formed to develop novel forms of polysialylated blood coagulation factors as part of more general programme to work together on extending the life of proteins and molecules to develop longer lasting drugs.
Baxalta agreed a US$32bn merger with UK-listed Shire Pharma in January but agreed the deal with Xenetic I Spetmeber last year.
Xenetic is entitled to up to US$100mln in milestone payments and royalties on future sales. Baxalta is also a major shareholder with an 8.7% stake.
Baxalta hopes to enrol thirty patients for this safety and dose tolerance trial.
Legal Disclaimer:
MENAFN provides the information “as is” without warranty of any kind. We do not accept any responsibility or liability for the accuracy, content, images, videos, licenses, completeness, legality, or reliability of the information contained in this article. If you have any complaints or copyright issues related to this article, kindly contact the provider above.